Protagenic Therapeutics

Protagenic Therapeutics, Inc. is a biopharmaceutical company in its pre-clinical phase, dedicated to discovering and formulating treatments for neuropsychiatric and mood disorders that are related to stress. Its flagship compound, PT00114, is a laboratory-produced variant of teneurin carboxy-terminal associated peptide, a naturally occurring brain signaling peptide recognized for its capacity to moderate excessive stress reactions. The firm was established in 2016 and maintains its principal office in New York, New York.